Randomized Trial Comparing Safety and Effectiveness of Cocoon and Amplatzer PFO Occluder Devices
in Adults With Stroke or Transient Ischemic Attack
Led by Giuseppe Tarantini · Updated on 2026-10-05
1260
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of two devices used to close a patent foramen ovale PFO in adults who have experienced a cryptogenic embolic stroke or transient ischemic attack TIA within the past year. This non-profit, single-blind, randomized clinical trial compares the Cocoon PFO Occluder with the Amplatzer PFO Occluder to help identify the best option for preventing recurrent neurological events associated with PFO. Up to 1260 participants will be enrolled across multiple European centers.
Participants are randomly assigned in a 31 ratio to receive either the Cocoon PFO Occluder or the Amplatzer PFO Occluder device through a percutaneous closure procedure. The procedure is performed under standard clinical practice, guided by echocardiography, and scheduled within 45 days after randomization, preferably within 14 days. After device implantation, participants follow dual antiplatelet therapy and receive recommended endocarditis prevention for six months. Both study groups undergo similar clinical and echocardiographic follow-up.
During the study, participants will have routine clinical evaluations and echocardiographic imaging to assess PFO closure at 6 months and monitor for safety and device performance. The main outcome measured is a composite of recurrent ischemic stroke, TIA, or all-cause death at 12 months post-procedure. Additional assessments include neurological and cardiovascular events, adverse events, quality of life, migraine days, and device-related markers. Participation lasts up to one year with ongoing follow-up visits.
CONDITIONS
Brief Title
Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA
Research Team
D
Daniela Ramaccini, PhD, PharmaD
F
Francesco Cardaioli, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adults aged over 18 and under 65 years, any gender
Confirmed patent foramen ovale (PFO) with normal or aneurysm type on imaging and right-to-left shunting
History of cryptogenic embolic stroke or transient ischemic attack (TIA) within the past 12 months confirmed by a neurologist
PFO size suitable for closure with Cocoon or Amplatzer devices
Informed consent given and agreement to complete follow-up and examinations
You will not qualify if you...
Stroke or transient ischemic attack caused by definite reasons unrelated to PFO
Right-to-left shunting from other causes like atrial septal defect or pulmonary arteriovenous shunt
History of atrial fibrillation/flutter, intracardiac thrombus, or tumor
Severe valve problems or prosthetic valves
Active infections such as endocarditis
Various cardiomyopathies or low left ventricular ejection fraction (<35%)
Recent myocardial infarction or unstable angina within 12 months
Previous intracardiac surgery or PFO closure
Significant arterial stenosis (>50%) supplying the infarcted area
Non-embolic stroke or other identified stroke causes
Severe kidney or liver impairment
Severe lung disease including pulmonary hypertension
Uncontrolled hypertension or diabetes
Contraindications to anticoagulants or antiplatelet drugs
Pregnancy, planned pregnancy within 12 months, or breastfeeding
Hypercoagulable states or progressive neurological diseases
Life expectancy under 12 months due to serious diseases
Device interference with heart or vascular structures
Psychiatric conditions affecting compliance
Participation in other investigational studies not completed
Inability to give informed consent
Poor stroke outcome (Modified Rankin score >3)
Unable to complete follow-up for the study duration
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 45 days after randomization for procedure; follow-up continues up to 12 months
Participants undergo percutaneous closure of patent foramen ovale using either the Cocoon PFO Occluder or Amplatzer PFO Occluder device, followed by dual antiplatelet therapy and recommended endocarditis prevention.
Regular clinical and echocardiographic assessments including a 6-month closure evaluation
Follow-up
Duration - 12 months after the procedure
Participants receive routine clinical evaluations to monitor for recurrent neurological events, device performance, and safety outcomes up to 12 months after the procedure.
Multiple follow-up visits including imaging and clinical assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study Evaluating Combined Cognitive and Balance Rehabilitation for Adults Recovering From Stroke
Using 5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease A Prospective Observational Cohort Study
Testing Caregiver-Assisted Strategy Training to Improve Daily Activities for Adults After Stroke in a Multi-Center Trial
Stroke Recovery Study Using EEG-Guided Muscle and Tongue Stimulation
Evaluating Brain-Computer Interface and Functional Electric Stimulation Therapy
Digital Intervention to Improve Depression and Executive Function After Stroke Using AKL-T01 and Coaching
Smart Home-Based Upper Limb Rehabilitation Using Robot and Task Training for Adults with Stroke and Spinal Cord Injuries
Study of Brain Activity Using Functional Near-Infrared Spectroscopy in Stroke Patients During Mirror Movement
Using a Mobile BrainBody Imaging System to Improve Post-Stroke Walking with a Robotic Device
Study on Intravenous Thrombolysis Using Alteplase or Tenecteplase for Acute Ischemic Stroke Treated Between 4.5 and 24 Hours After Onset
Evaluating a Telemedicine-Supported Integrated Care Model Led by Rural Doctors to Reduce Cardiovascular and Cerebrovascular Events in Older Adults at High Stroke Risk in China
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.